Join the Migraine Prevention group to help and get support from people like you.
Migraine Prevention News (Page 2)
ACP Issues Clinical Guideline for Pharmacologic Prevention of Episodic Migraine
MONDAY, Feb. 10, 2025 – In a clinical guideline issued by the American College of Physicians and published online Feb. 4 in the Annals of Internal Medicine, recommendations are presented regarding...
Minority Children Less Likely to Be Diagnosed With Migraine in Emergency Department
WEDNESDAY, Feb. 5, 2025 – Compared with non-Hispanic White (NHW) children, non-Hispanic Black (NHB) and Hispanic/Latino (HL) children with a headache diagnosis in the emergency department have lower...
Too Often, ER Docs Don't Spot Migraines in Minority Kids
THURSDAY, Feb. 6, 2025 – Kids and teens can also get migraines, but Black and Hispanic children seen in ERs are more likely to have their condition go undiagnosed, new research shows. That's...
FDA Approves Symbravo for Acute Treatment of Migraine in Adults
WEDNESDAY, Feb. 5, 2025 – The U.S. Food and Drug Administration has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults. The approval was ...
Beta Blocker Propranolol Might Reduce Migraine Stroke Risk
MONDAY, Feb. 3, 2025 – A common drug used to prevent migraines might have an additional benefit – protecting women against stroke. Women taking the beta blocker propranolol to ward off migraines...
Propranolol May Reduce Overall Stroke Risk in Women With Migraine
FRIDAY, Jan. 31, 2025 – Propranolol is associated with a reduced risk for overall stroke among women with migraine, with a more pronounced protective effect for ischemic stroke, according to a study...
Quick Fix? New Migraine Medicine, Qulipta, May Start Working Right Away
THURSDAY, Dec. 26, 2024 – Migraine patients often suffer a long time before docs zero in on the best dosage for drugs designed to prevent their terrible symptoms. But a recently approved daily...
Atogepant Superior for Efficacy, Functional Measures in Migraine
THURSDAY, Dec. 26, 2024 – For adults with migraine, atogepant 60 mg once daily was superior to placebo for efficacy and functional measures of treatment across three trials, according to research...
Older Adults With Migraine Experienced Higher Depression Risk During Pandemic
TUESDAY, Nov. 26, 2024 – During the pandemic, older adults with migraine experienced a substantial increase in the risk for depression, regardless of previous history, than before the pandemic and...
FDA Approves Nerivio for Migraine Treatment in Children Aged 8 Years and Older
FRIDAY, Nov. 22, 2024 – The U.S. Food and Drug Administration has expanded the age indication for Nerivio, making it the first and only remote electrical neuromodulation (REN) wearable for migraine...
Clinical Practice Guideline Updated for Migraine, Tension-Type Headache
TUESDAY, Oct. 29, 2024 – In a clinical practice guideline (CPG) issued by the U.S. Department of Veterans Affairs and U.S. Department of Defense and published online Oct. 29 in the Annals of...
Study Addresses Differentiating Meniere Disease, Vestibular Migraine
THURSDAY, Oct. 3, 2024 – The dissociation between pathological caloric testing and a normal video head impulse test can differentiate between Meniere disease (MD) and vestibular migraine (VM),...
Review Compares Drug Interventions for Acute Migraine Treatment
MONDAY, Sept. 23, 2024 – All active interventions show superior efficacy to placebo for freedom from pain, and most do for sustained pain freedom, for the acute treatment of migraine among adults,...
Erenumab Effective for Nonopioid Medication Overuse Headache in Chronic Migraine
WEDNESDAY, Sept. 18, 2024 – Monthly use of erenumab injections (140 mg) is safe and effective in achieving medication overuse headache (MOH) remission in patients with nonopioid chronic migraine...
FDA Approves Eprontia (topiramate) Oral Solution for Epilepsy and Preventive Treatment of Migraine
WOBURN, MA, November 8, 2021 – Azurity Pharmaceuticals, Inc. a private specialty pharmaceutical company focused on developing innovative products to meet the unique needs of patients with underserved ...
Further information
Related condition support groups
Related drug support groups
clonazepam, lisinopril, metoprolol, bupropion, amitriptyline, amlodipine, propranolol, Topamax, lamotrigine, view more... pregabalin, Depakote, atenolol, topiramate, baclofen, clonidine, nortriptyline, Botox, Emgality, Aimovig, erenumab, Ajovy, verapamil, Qulipta, nifedipine, Nurtec ODT